QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 what-happened-with-bio-path-stock-today

Bio-Path shares ended Wednesday's session slightly higher after the company provided an update from its ongoing Phase 1/1b ...

 bio-path-holdings-q2-2024-gaap-eps-116-beats-154-estimate

Bio-Path Holdings (NASDAQ:BPTH) reported quarterly losses of $(1.16) per share which beat the analyst consensus estimate of $(1...

 roth-mkm-reiterates-buy-on-bio-path-hldgs-maintains-20-price-target

Roth MKM analyst Philip Shen reiterates Bio-Path Hldgs (NASDAQ:BPTH) with a Buy and maintains $20 price target.

 bio-path-reports-meaningful-progress-across-key-clinical-trials-in-multiple-cancer-indications

Peter H. Nielsen, President and Chief Executive Officer of Bio-Path, said, "With the increased clinical data that we have g...

 why-bio-path-stock-is-climbing-today

Bio-Path Holdings shares are trading higher Friday after the company announced interim results from its Phase 2 study of prexig...

Core News & Articles
Market-Moving News for June 14th
06/14/2024 12:34:25

ADBE: 16% | Adobe shares are trading higher following better-than-expected Q2 earnings and strong guidance. BPTH: 46% | Bio-Pa...

 bio-path-holdings-reveals-interim-results-from-phase-2-study-of-prexigebersen-in-combination-with-decitabine-and-venetoclax-for-treatment-of-acute-myeloid-leukemia

The company presented interim results from the Company's Phase 2 study of prexigebersen (BP1001) in combination with decita...

 bio-path-holdings-announces-4m-private-placement-of-1809955-shares-of-its-common-stock-series-a-warrants-to-purchase-up-to-1809955-shares-of-common-stock-and-short-term-series-b-warrants-to-purchase-up-to-1809955-shares-of-common-stock-at-a-purchase-price-of-221

Bio-Path Holdings, Inc. (NASDAQ:BPTH) ("Bio-Path" or the "Company"), a biotechnology company leveraging its pro...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION